Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The company is headquartered in Perth, Western Australia. The company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its prescription (Rx) business, including insomnia, autism and chronic non-cancer pain. Its lead product, Zenivol, is a cannabinoid-based medicine for the treatment of chronic insomnia. The company also provides formulations under the HOPE brand. The firm is engaged in human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the United States. The company is also focused on pre-clinical research examining the effects of cannabinoids in breast, brain and pancreatic cancer, as well as research and development of cannabinoids to treat diabetes-associated cognitive diseases. Its SprinjeneCBD toothpaste product is a hemp-derived, oral care product containing cannabinoids, based on the technology of blackseed oil.
Zelira Therapeutics (ASX: ZLD)
- Home
- Zelira Therapeutics (ASX: ZLD)
Here are the latest articles on Zelira Therapeutics (ASX: ZLD)
Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
July 11, 2024
A new drug seeking to treat irritability associated with Autism Spectrum Disorder (ASD) could soon be making its way to clinical trials in healthy volunteers after Zelira Therapeutics (ASX: ZLD) concluded a positive round of discussions with the United States Food and Drug Administration (FDA) on a study design. The proposed clinical trials are for
Zelira enrols sixty patients for diabetic nerve pain drug trial as it attempts to overthrow major pharma company
November 21, 2022
Biopharmaceuticals company Zelira (ASX: ZLD) is taking a stab at redemption. After a misstep this July by not announcing its German expansion, the Company lost shareholder trust. Now, it is attempting to get it back with new milestones revealed on time for its clinical trials targeting diabetic nerve pain. The trial has been designed as
Cannabis toothpaste is a thing, and Zelira Therapeutics are commercialising it
September 8, 2020
Furthering their expertise in the field of cannabinoid-based therapeutics, Zelira Therapeutics (ASX: ZLD) is set to tap into the oral care market with the launch of hemp derived toothpaste in the United States. The toothpaste formulation was created by Sprinjene CEO and Founder, Dr Sayed Abrahim who developed the oral care product which is gluten-free,
Zelda to launch clinical trials testing cannabis as solution to insomnia
November 7, 2019
Australian bio-pharmaceutical developer Zelda Therapeutics (ASX: ZLD) has now fully enrolled insomnia sufferers into clinical trials where the Company aims to use cannabis as a treatment for clinically diagnosed patients. This set of trials will be completed in collaboration with the University of Western Australia (UWA) Centre for Sleep Science. The trials will aim to
Recent Articles
